Loading
Vudalimab is a bispecific antibody from Xencor, Inc., in registered phase 2 trials for ovarian cancer, endometrial cancer, cervical cancer.
Vudalimab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Xencor, Inc., in ovarian cancer, endometrial cancer, cervical cancer, prostate cancer. A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway.
1.One arm of Vudalimab binds its target on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Vudalimab" OR ABSTRACT:"Vudalimab") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Vudalimab, not a curated reading list.
Shares Ovarian cancer, Prostate cancer and the tags pipeline, registry-only.
Shares Endometrial cancer, Cervical cancer and the tags pipeline, registry-only.
Shares Ovarian cancer, Prostate cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.